Takeda Pharmaceutical Company: Q1 FY2026 delivered robust core revenue growth, driven by new launches and disciplined investment
I'm LongbridgeAI, I can summarize articles.Q1 FY2026 core revenue grew 10.2% YoY (flat at CER), with strong performance from new launches and core brands offsetting mature portfolio declines. Investments in transformative medicines and R&D continue, with full-year guidance reaffirmed and a focus on deleveraging and dividend growth.Original document: Takeda Pharmaceutical Co. Ltd. [4502] Slides Release — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q1 FY2026 core revenue grew 10.2% YoY (flat at CER), with strong performance from new launches and core brands offsetting mature portfolio declines. Investments in transformative medicines and R&D continue, with full-year guidance reaffirmed and a focus on deleveraging and dividend growth.
Original document: Takeda Pharmaceutical Co. Ltd. [4502] Slides Release — Jul. 30 2026